Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3544751 | 0.84 | IGF1R (0.34) | IGF1R | |
| SCHEMBL3536879 | 0.84 | IGF1R (0.34) | IGF1R | |
| SCHEMBL3543046 | 0.83 | MEN1 (0.31) | IGF1R | |
| SCHEMBL3543266 | 0.82 | INSR (0.33) | IGF1R | |
| SCHEMBL3542565 | 0.82 | INSR (0.33) | IGF1R | |
| SCHEMBL3536169 | 0.79 | IGF1R (0.32) | IGF1R | |
| SCHEMBL3538974 | 0.79 | INSR (0.30) | IGF1R | |
| SCHEMBL13372644 | 0.77 | IGF1R (0.32) | IGF1R | |
| SCHEMBL3542697 | 0.76 | IGF1R (0.32) | IGF1R | |
| SCHEMBL402610 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7648987-B2 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | CDK1, MAP4K2, MAP4K3 | IGF1R 3009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.